Shareholder Information

MDxHealth is a multinational healthcare company that provides actionable epigenetic information to personalize the diagnosis and treatment of cancer.

The company’s tests are based on proprietary gene methylation (epigenetic) technology and assist physicians with the diagnosis of cancer, prognosis of recurrence risk, and prediction of response to a specific therapy.

Corporate Presentation

An overview of the most recent information about MDxHealth can be found in the company’s periodic corporate presentation slides and can be downloaded here.

Corporate Governance Charter

MDxHealth attaches great value to corporate governance practices. On September 7, 2011, our board of directors approved the current version of MDxHealth’s Corporate Governance Charter. The Charter has been drafted in accordance with the principles and the provisions of the Belgian Corporate Governance Code 2009 issued on March 12, 2009 by the Corporate Governance Committee.

The full text of MDxHealth’s Corporate Governance Charter can be downloaded here.

MDxHealth is listed on the Euronext under the ticker symbol MDXH.

MDxHealth has been listed on Euronext since June 2006. There is only one class of shares in the company (common shares) and all shares have the same rights and voting representation. There are no other financial instruments issued by the company other than stock options issued to employees, directors, and some consultants.

Code of Ethics

The full text of MDxHealth’s Code of Ethics can be downloaded here.

Dealing Code

As a listed company, MDxHealth must comply with rules governing insider trading. The company’s dealing code can be found here.

Articles of Association

The Articles of Association are periodically updated. The latest version (May 15, 2020) can be found here:

Share capital history

The history of the share capital issuance since the inception of the company can be found here:

Transparency Declarations of the largest shareholders

The table below provides an overview of the shareholders that filed a notification with MDxHealth SA pursuant to applicable transparency disclosure rules. Although the applicable transparency disclosure rules require that a disclosure must be made by each person passing or falling under one of the relevant thresholds, it is possible that the information below in relation to a shareholder is no longer up-to-date. The percentages of voting rights mentioned in the table have been calculated on the basis of the currently outstanding shares.

SHAREHOLDER (OR PARTY REPRESENTING SHAREHOLDERS)MVM PARTNERS LLPBIOVEST COMM.VAVALIANCE ASSET MANAGEMENTSCORPIAUX BVBA
% OF OUTSTANDING SHARES22.23%13.99%12.30%4.26%
SITUATION AS OFMay 15,2020June 26,2015May 15,2020May 15,2020
NOTIFICATION RECEIVEDMay 18,2020July 1,2015May 21,2020June 2,2020
NOTIFICATION FORMClick here to view formClick here to view formClick here to view formClick here to view form

*Percentage calculated as per the date of the relevant transaction and taking into account the total number of outstanding shares as per such date

Each natural or legal person acquiring or transferring MDxHealth’s shares is required to notify MDxHealth and the Financial Services and Markets Authority (FSMA) each time their shareholding crosses a threshold of three percent (3%) of the total number of outstanding shares (the denominator). Such notification is also required each time, as a result of an acquisition or transfer a threshold of five percent (5%) and a multiple of five percent (5%) is crossed. Complete information regarding this requirement is found in Article 14 of MDxHealth’s articles of association.

The transparency notifications should be reported within 5 business days of crossing the threshold by following the procedures outlined on the FSMA website found here.

A copy of the transparency notification should also be emailed and faxed to the company, to the attention of: Ron Kalfus, Chief Financial Officer, at ir@mdxhealth.com and fax +32 4 259 78 75.

Special and Extraordinary Shareholders' Meeting (July 30, 2020)

Convening Notice: English I Français 

Explanatory Note: English I Français 

Proxy Form: English/Français

Voting by Mail Form: English/Français

Overview of Outstanding Voting Rights: Français I English

Special Board Report pursuant to Article 7:199 of the Belgian Companies and Associations CodeEnglish I Français 

Previous Shareholder Meetings

PDF icon AGM Minutes – May 28 2020 – EN (free translation)

PDF icon AGM Minutes – May 28 2020 – FR

PDF icon EGM Minutes – May 28 2020 – FR

PDF icon AGM 2019 – minutes (French) FINAL SIGNED.pdf

Paying Agent

The financial service for the shares of the company is provided in Belgium by ING. Shareholders should inform themselves about the costs that other financial intermediaries may charge in connection with paying agency services.

Special Reports of the Board and Auditor

Report of the Statutory Auditor in relation to the equity investment by MVM, dated May 15, 2020 (EN)

Report of the Statutory Auditor in relation to the equity investment by MVM, dated May 15, 2020 (FR)

Board Report in relation to the equity investment by MVM, dated May 15, 2020 (EN)

Board Report in relation to the equity investment by MVM, dated May 15, 2020 (FR)

Auditor Report I art 596

Auditor Report II art 596

2019-09-Auditors Report art 596

2019-09-EN-Board Report art 596

2019-09-FR-Board Report art 596

2018-03-Auditors Report art 596

2018-03-EN-Board Report art 596

2018-03-FR-Board Report art 596

006 Board Report 596 (FR)[5].pdf

604 Board Report (FR) exec.pdf

604 Board Report (FR).pdf

583 596 598 Board Report and Plan (EN).pdf

583 596 598 Board Report and Plan (FR).pdf

R Mdx art 596-598 Plan d’options sur Action May 2017 – 2.500.000 SOP.pdf

Rapport special du conseil dadministration.article596.Nov_.2016.EN_.pdf

Rapport special du conseil dadministration.article596.Nov_.2016.EN_.pdf(FR).pdf

Rapport du commissaire, article 596, 31 octobre 2006 .pdf

Rapport du conseil d’administration. article 604 avril 2016.pdf

604 Board Report (FR) exec.pdf

Rapport du Commissaire, article 602, 18 septembre 2015.pdf

Rapport du Conseil d’Administration, article 602, 18 septembre 2015.pdf

Report of the Board, article 602, September 18, 2015.pdf

Rapport du commissaire – article 596, 23 juin 2015.pdf

Rapport du conseil d’administration, 23 juin 2015.pdf

Rapport du conseil d’administration, 4 novembre 2014.pdf

Rapport du conseil d’administration – articles 583-596-598 – 30 avril 2014.pdf

Rapport du commissaire – articles 596-598 – 30 avril 2014.pdf

Rapport du commissaire, articles 596 et 598, 24 juin 2013.pdf

Rapport du conseil d’administration, 24 juin 2013.pdf

Rapport du conseil d’administration, article 604, 30 avril 2013.pdf

Rapport du commissaire, articles 596 et 598, 28 juin 2012.pdf

Rapport du conseil d’administration, articles 603 juncto 596 et 598, 28 juin 2012.pdf

Rapport du conseil d’administration, articles 583:596:598, 18 avril 2012.pdf

Rapport du commissaire, articles 596:598, 19 avril 2012.pdf

Rapport du conseil d’administration, articles 583:596:598, 27 mai 2011.pdf

Rapport du commissaire, article 596, 27 mai 2011.pdf

Rapport du commissaire, article 596, 4 avril 2011.pdf

Rapport du conseil d’administration, article 603 juncto l’article 596, 4 avril 2011.pdf

Rapport du commissaire, Art. 582:596:598, 10 mai 2010.pdf

Rapport du conseil d’administration, articles 582:583:596:598, 21 juin 2010.pdf

Rapport du conseil d’administration, article 633, 10 mars 2010.pdf

Rapport du commissaire, article 596, 27 janvier 2009.pdf

Rapport du conseil d’administration, articles 583:596, 27 janvier 2009.pdf

Rapport du commissaire, article 596, 15 décembre 2008.pdf

Rapport du conseil d’administration, articles 603:596:589, 15 décembre 2008.pdf

Rapport du conseil d’administration, articles 583:596:589, 30 mai 2008 .pdf

Rapport du commissaire, article 596, 26 mai 2008.pdf

Rapport du conseil d’administration, articles 604, 27 mars 2008.pdf

Rapport du conseil d’administration, articles 603:596, 15 octobre 2007.pdf

Rapport du commissaire, article 596, 15 octobre 2007 .pdf

Rapport du conseil d’administration, articles 583:596:598, 25 mai 2007 .pdf

Rapport du commissaire, articles 596:598, 21 mai 2007 .pdf

Rapport du conseil d’administration, articles 583:596, 18 avril 2007.pdf

Rapport du commissaire, article 596, 16 avril 2007 .pdf

Rapport du conseil d’administration, articles 583:596, 8 november 2006.pdf

Investor Relations Contact

For all investor related questions please call or email:

LifeSci Advisors (IR & PR)

US: +1 949 646 597 6989
ir@mdxhealth.com